TLR9 and ulcerative colitis: This protective role of TLR9 is demonstrated by positive outcomes from experimental treatments using synthetic CpG-based TLR9 agonists on adults and mice with ulcerative colitis, reducing symptoms by targeting the imbalance between mucosal TLR9 and TLR4 activation [34].